01 December 2008 By:
Thomas Hesterkamp
|
Using fragments, it is possible to exhaustively screen a target site to pick the best matching fragment for optimization.

01 December 2008 By:
Joseph F. deSpautz, Kenneth S. Kovacs
|
With operating efficiencies increasingly dependent on 'right first time', there is a need to change the status quo in the way processes are controlled.

01 December 2008 By:
Daniel Burnett, Nishil Malde, Daryl Williams
|
Amorphous materials in pharmaceutical formulations yield complex and challenging problems concerning the performance, processing and storage of these products.

01 March 2008 By:
David Ager
|
The time-to-market constraints associated with modern drug development restricts the methodologies and reactions that can be used to make an API. In addition, there are also health and safety issues coupled with environmental factors to consider. An ideal reaction would use an innocuous catalyst to convert all of the substrate to the desired product. However, we are far from this ideal situation. A catalytic reaction has many advantages compared with one that uses a stoichiometric reagent: one molecule of catalyst can produce many molecules of product. This decreases the amount of reagent needed, which can have positive consequences for waste and cost.

01 December 2007 By:
Brigitte Staecker, Michael Kelly
|
A checklist of how to achieve regulatory compliance by validation of laboratory information management systems. Validation costs and cost-effective validation strategies are considered for pharmaceutical manufacturers to validate their systems and maintain a validated state for continued compliance.

01 December 2007 By:
Brendan Fish, Richard Williams
|
The scale-up of manufacturing processes to clinical production can be complicated and expensive, with many issues to consider. This article describes some of the common and less obvious pitfalls encountered by biopharmaceutical companies when scaling up protein production processes, and how to avoid them.

01 December 2007 By:
Colin Walsh
|
Is consolidated distribution the key to combating counterfeit drugs and parallel imports?

01 June 2007 By:
Jon Mowles, Lisa Lim
|

01 June 2007 By:
Gail Sofer, Laura C. Chirica
|
Improved feedstream titres are driving a demand for increased downstream processing productivity as manufacturers seek to lower the costs of monoclonal antibodies (MAbs). The unique selectivity of protein A has enabled platform technologies for MAb purification. Platform technologies and chromatography resin improvements can help manufacturers achieve rapid and economical process development and scale-up. A multiprong approach can enable downstream process scientists to enhance productivity.
